Why Shattuck Labs Stock Flew Nearly 5% Higher on Friday
An analyst initiated coverage of the biotech with a buy recommendation.
Overview
A new analyst note was the key factor behind the mini-rally in Shattuck Labs (NASDAQ: STTK) stock on the last trading day of the week. The clinical-stage biotech's shares closed the day almost 5% higher, thanks mainly to that research.
Early Friday morning, Brian Cheng of JPMorgan Chase's J.P. Morgan published his inaugural take on Shattuck. He rated the stock an overweight (read: buy) at a price target of $10 per share. That's nearly 35% higher than the biotech's most recent closing level.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
Related Articles
- Oracle Just Hit a New 52-Week Low. Wall Street's Average Target Is Still More Than Double the Stock.
- Is SoFi Technologies Stock a Bargain After Its Big Drop, or a Falling Knife?
- Elon Musk Wouldn't Rule Out a Tesla-SpaceX Merger on the July 22 Earnings Call. Here's What It Would Mean for the Shares You Own Today.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.